Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 748

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 748
---
 ☐Articles have been deleted.                                                                                                                                                             
 ☐Other.                                                                                                                                                                                  
 The articles have been amended as follows: (provide article numbers, if available)Article I, the name of the entity is Pelthos Therapeutics Inc.(attach additional page(s) if necessary) |

| 6. Signature:                                                       
 (Required)                                                          |     | X                                                                                                                                                                                                                                                                                                                                                                                                                                                         |     | Chief Executive Officer and Chief Financial Officer |
|                                                                     |     | Signature of Officer or Authorized Signer                                                                                                                                                                                                                                                                                                                                                                                                                 |     | Title                                               |
|                                                                     |     | X                                                                                                                                                                                                                                                                                                                                                                                                                                                         |     |                                                     |
|                                                                     |     | Signature of Officer or Authorized Signer                                                                                                                                                                                                                                                                                                                                                                                                                 |     | Title                                               |
|                                                                     |     | *If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof. |     |                                                     |
| Please include any required or optional information in space below: 
 (attach additional page(s) if necessary)                            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |     |                                                     |

This form must be accompanied by appropriate fees.

C-2

#### TABLE OF CONTENTS

#### Annex D

### CHANNEL THERAPEUTICS CORPORATION
<div align='center'>2023 EQUITY INCENTIVE PLAN

As Amended and Restated effective as of April 16, 2025</div>

1. PURPOSE

The purpose of this 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the “Plan”) is to encourage key service providers of Channel Therapeutics Corporation (the “Company”) and its Subsidiaries (as defined below) to continue their association with the Company by providing favorable opportunities for them to participate in the ownership of the Company and its Subsidiaries and in its future growth through the granting of equity ownership opportunities and incentives based on the Company’s Common Stock (as defined below) that are intended to align their interests with those of the Company’s shareholders (“Awards”). Each person who is granted an Award under the Plan is deemed a “Participant.”

The term “Subsidiary” as used in the Plan means a corporation, company, partnership or other